Developing new materials to improve cancer treatment for multiple myeloma
Official title: Engineering Biomaterials to Modulate the Tumor Immune Microenvironment
Funded at Sloan-Kettering Inst Can Research · NIH-11232006 · Data updated 2026-11-12
This study is exploring new ways to treat multiple myeloma by using special materials to deliver targeted therapies that can help make current treatments work better, giving patients more options to fight their cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $100,760 |
| NIH project number | 4K00CA284294-03 |
| Project ID | NIH-11232006 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with multiple myeloma who have not responded well to current therapies.
✕Less likely to help
Patients with other types of cancers or those who have not been diagnosed with multiple myeloma may not benefit from this research.
What this research studies
This research focuses on finding innovative therapies for multiple myeloma, a type of blood cancer that is often resistant to current treatments. The approach involves engineering biomaterials that can effectively deliver RNA interference therapies to target specific proteins that help cancer cells survive and spread. By inhibiting these proteins, the goal is to enhance the effectiveness of existing treatments and overcome drug resistance. Patients may benefit from new therapeutic options that are designed to be more effective against their cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for multiple myeloma, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Other research has shown promise in using RNA interference therapies for cancer treatment, indicating that this approach could be a viable option.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Figueroa-Espada, Christian Gabriel — Sloan-Kettering Inst Can Research
- Study coordinator: Figueroa-Espada, Christian Gabriel
Related research
Other NIH-funded projects on the same topics.
-
Understand how skeletal muscle nuclei specialize and arrange themselves for proper muscle function
A study to uncover how the hundreds of nuclei in skeletal muscle fibers acquire different roles and positions to keep muscles strong and healthy.
-
Genomic profiling and outcomes of cancers in World Trade Center-exposed survivors and responders
This project looks at the genetic makeup and real-world cancer outcomes in people exposed to the World Trade Center disaster to understand how their cancers behave and respond to treatments.
-
Meaning-Centered Psychotherapy for Mexican Patients with Advanced Cancer
A cancer center in Mexico will test a culturally adapted therapy to help Mexican patients with advanced cancer find meaning, peace, and purpose at the end of life.
-
High-specificity genome-scale cell-surface proteomics to find tumor targets
A cancer research project is trying to map all the proteins on the surface of ultra-rare sarcoma cells to find safe, targeted ways to treat them.
-
Priorities for testing and choosing combination therapies in rhabdoid tumors to guide clinical trials
A coordinated, multi-site effort will rigorously test promising drug combinations in rhabdoid tumors to identify the most promising options for future patient trials.
-
ecDNA in Cancer: Understanding and targeting circular DNA that drives tumor growth
A cancer-focused project to understand how extrachromosomal DNA helps tumors grow and resist treatment, and to develop new ways to target these mechanisms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.